Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc., a biopharmaceutical company specializing in immune-oncology vaccines and drug delivery technologies, has strengthened its global patent portfolio with new patents and allowances across various jurisdictions. These advancements support the company’s vaccine enhancer platform and ADC platform technology, which are showing promise in pre-clinical studies for treating various cancers and are moving towards Phase I clinical trials. The company’s robust patent protection further solidifies its position in the development and commercialization of innovative cancer therapies.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
